Supplemental Comment from Kenvue Brands LLC part 7 of 9
AnonymousOtherBusiness
Summary: Kenvue Brands LLC submitted a supplemental response regarding pediatric medical product safety and postmarket monitoring. The comment provides information on FDA's role in monitoring pediatric safety and includes an unrelated scientific study on acetaminophen neurotoxicity.
Kenvue Brands LLC’s supplemental response to the Citizen Petition part 7 of 9
Attachments
- Parker et al. (2024)
- Pediatric Medical Product Safety FDA (PDF)
- Peralta-Marzal et al. (2021)
- Posadas et al. (2010) (PDF)
- Raijmakers et al. (2001)
- Randles et al. (2016)
- Rao and Andrade (2011) (PDF)
- Raz et al. (2015) (PDF)
- Rigobello et. al. (2021) (PDF)
- Rimland (2000) (PDF)
- Roberts et al. (2013)
- Roberts et al. (2019)
- Rollins et al. (1979)
- Rosen et al. (2007)
- Saad et al. (2016) (PDF)
- Saeedan et al. (2018) (PDF)
- Sarkar et al. (1989)
- Schneider et al. (2021) (PDF)
- Schultz and Gould (2016) (PDF)
- Schultz et al. (2008)